Medigene reports outcome of Annual General Meeting
- Shareholders approve all resolutions with a high majority
- Creation of new Authorized Capital resolved
Martinsried/Munich, 14 August 2015. Medigene AG (MDG1, Frankfurt, Prime Standard) announces that at the Annual General Meeting of the company all resolutions were approved with a high majority.
The shareholders of Medigene AG decided with a vote of 92,9% to revoke the Authorised Capital 2012/I and create new Authorised Capital 2015/I for an amount of up to 9,822,996 shares and therefore provide the company with operational and strategic flexibility. Moreover, the members of Medigene's Executive and Supervisory Board were discharged for the fiscal year 2014 by a majority of over 98%, respectively.
Dr. Frank Mathias, Chief Executive Officer of Medigene AG, comments: "We are very pleased with the broad support of our shareholders. The approval of our strategic proposal enables us to further develop the company, especially in the innovative field of immunotherapies. On behalf of the Board I thank the shareholders of Medigene AG for their vote of confidence."
For more information please follow the link: www.medigene.com/media-investors/annual-general-meeting/2015
Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. Medigene concentrates on the development of personalized T cell immunotherapies with a focus on hematological malignancies. Medigene is the first German biotech company to have revenues from a marketed product, which is distributed by commercial partner companies. Medigene has advanced drug candidates which are licensed to partners and additional candidates in clinical development. The company is developing highly innovative treatment platforms concentrating on cancer and autoimmune diseases. For more information, please visit www.medigene.com.
This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene®, Veregen®, EndoTAG® and RhuDex® are registered trademarks of Medigene AG. Medigene ImmunotherapiesTM is a registered trademark of Medigene Immunotherapies GmbH. Trianta ImmunotherapiesTM is a registered trademark of Medigene Immunotherapies GmbH. These trademarks may be owned or licensed in select locations only.
Julia Hofmann, Anja Clausnitzer
Tel.: +49 - 89 - 20 00 33 - 33 01
To unsubscribe from the press release distribution list, please go to: www.medigene.de/unsubscribe